Journal
TOXICOLOGY AND APPLIED PHARMACOLOGY
Volume 407, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.taap.2020.115247
Keywords
Psoriasis; Thymol; Pruritus; Inflammation; TRPM8
Categories
Funding
- National Major Scientific and Technological Special Project for Significant New Drugs Development of China [2017ZX09301060]
- Hubei Provincial Technical Innovation Program [2017AHB067, 2018ABA093]
- Special Fund for National Ethnic Affairs Commission of the People's Republic of China [MZR20001]
- Special Fund Basic Scientific Research of Central Colleges, South-Central University for Nationalities [CZJ19001]
Ask authors/readers for more resources
Psoriasis is a highly prevalent chronic dermatitis, characterized by widespread skin inflammation and spontaneous itch. Given the adverse reactions and drug dependence of current treatment, new drugs for psoriasis therapy are urgently needed. This study aims to explore the anti-psoriatic effects of thymol in imiquimod (IMQ) induced mice, and elucidate the potential mechanisms for its therapeutic activities. Thymol reduced the scratching behavior in IMQ mice, and activated Ca2+ response in cervical DRG neurons via TRPM8 channel. Also, thymol alleviated psoriasis-like skin lesions, and attenuated the enhanced infiltration of dermal neutrophils, dendritic cells (DCs) and Th17 cells. In addition, it reversed the upregulated expression of pro-inflammatory cytokines in the skin (TNF-alpha, IL-22, IL-23, IL-17A, IL-17F, IL-17C, IL-6, IL-1 beta and IFN-gamma) and serum (TNF-alpha, IL-6, IL-1 beta, IL-17A and IFN-gamma). Our results indicated that thymol can effectively ameliorate pruritus and the symptoms of psoriasis-like inflammation induced by IMQ, which makes it a promising drug for the treatment of psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available